DDReg pharma

Quailty Driven by Passion

All Category

Home » All Category » Page 14

Specifications for In Vitro Diagnostic Devices

In vitro diagnostic medical devices (IVD devices) are an integral part of the healthcare system. They are typically used to analyze samples that are collected from the human body (i.e., saliva, blood, tissue, and urine) and help in diagnosing, screening, and monitoring various conditions. IVD devices are subjected to different regulations that specify different requirements […]

Specifications for In Vitro Diagnostic Devices Read More »

Faster Access to Clinical Trial Information in Europe

Improving access to clinical trial information is critical in order to advance medical research while also ensuring patient safety. Enhanced transparency can not only accelerate innovation but also empower various stakeholders to make appropriate and informed decisions in order to progress medical research forward. The European Medicines Agency (EMA) has introduced several improvements in the

Faster Access to Clinical Trial Information in Europe Read More »

The Use of EDDO to Ensure Drug Delivery Function

When it comes to ensuring the safety and effectiveness of medical devices intended to deliver drugs, understanding Essential Drug Delivery Outputs (EDDO) is important. The advent of drug-device combination products has necessitated the development of robust guidelines to ensure safety, efficacy, and performance. One such crucial aspect of these combination products is the Essential Drug

The Use of EDDO to Ensure Drug Delivery Function Read More »

Emerging Drug Safety Technology Program

Pharmacovigilance practices are associated with several challenges related to collection of safety data, processing, assessment, and volume of patient safety data. As technological disruptors- like artificial intelligence (AI)- develop, so do the solutions to tackle such challenges. This leads to more efficient pharmacovigilance (PV) systems and processes that ultimately enhance drug safety monitoring. Whether it

Emerging Drug Safety Technology Program Read More »

Machine Learning-Enabled Medical Devices

Ensuring Transparency for Machine Learning-Enabled Medical Devices

Transparency in Machine Learning-Enabled Medical Devices (MLMDs) refers to the degree to which relevant information about a device—such as its intended use, the development process, performance, and logic—is clearly communicated to stakeholders.  Why is this important? To help the development of safe, effective, and high-quality AI/ML learning technologies. These may learn from real-world data and

Ensuring Transparency for Machine Learning-Enabled Medical Devices Read More »

Clinical Evaluation of Orphan Medical Devices

In the European Union, the Medical Device Coordination Group (MDCG) continues to address unique challenges in the medical field, by bringing life-changing orphan medical devices to patients who suffer from rare conditions. These devices that are intended for a small number of individuals are subject to various hurdles in their development and market introduction. The

Clinical Evaluation of Orphan Medical Devices Read More »

Safety Testing of Allogeneic Cells used in Cell Based Medical Products

Cell based medicinal products use a single source of cells to treat multiple patients. For example, allogeneic cell therapies use donor cells to create a Master Cell Bank (MCB) that are then processed to be used in different kinds of therapies. The use of allogeneic cells to develop medicinal products and therapies demands rigorous testing

Safety Testing of Allogeneic Cells used in Cell Based Medical Products Read More »

Recommendations for the use of Animal & Human Derived Materials in Cell and Gene Therapy Products

The number of cell and gene therapies coming into the market each year is increasing steadily. An article published by McKinsey and Company in 2022 expected as many as 21 cell therapy and 31 gene therapy launches in 2024 itself. The growing focus on cell and gene therapies (CGT) presents a unique set of challenges to

Recommendations for the use of Animal & Human Derived Materials in Cell and Gene Therapy Products Read More »

Accelerating Product Registration with SFDA’s Priority Review

It is important for regulatory agencies to implement priority review processes in order to expedite drug approval processes. This ensures fast access to safe innovative treatments and life-saving medicines. By streamlining drug review processes that address unmet medical needs, or offer better treatment options compared to existing therapies, these processes can accelerate patient access. This

Accelerating Product Registration with SFDA’s Priority Review Read More »